Table of Contents
Chemotherapy Research and Practice
Volume 2013, Article ID 360624, 7 pages
http://dx.doi.org/10.1155/2013/360624
Research Article

Lomustine Analogous Drug Structures for Intervention of Brain and Spinal Cord Tumors: The Benefit of In Silico Substructure Search and Analysis

University of Nebraska, College of Arts & Sciences, Durham Science Center, 6001 Dodge Street, Omaha, NE 68182, USA

Received 12 February 2013; Revised 12 March 2013; Accepted 28 March 2013

Academic Editor: Vassilios A. Georgoulias

Copyright © 2013 Ronald Bartzatt. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. A. Alomar, “Clinical manifestation of central nervous system tumor,” Seminars in Diagnostic Pathology, vol. 27, no. 2, pp. 97–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. I. T. Gavrilovic and J. B. Posner, “Brain metastases: epidemiology and pathophysiology,” Journal of Neuro-Oncology, vol. 75, no. 1, pp. 5–14, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. C. H. Lee, K. W. Jung, H. Yoo, S. Park, and S. H. Lee, “Epidemiology of primary brain and central nervous system tumors in Korea,” Journal of Korean Neurosurgical Society, vol. 48, no. 2, pp. 145–152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. R. Geyer, R. Sposto, M. Jennings et al., “Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group,” Journal of Clinical Oncology, vol. 23, no. 30, pp. 7621–7631, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. R. J. Packer, A. Gajjar, G. Vezina et al., “Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma,” Journal of Clinical Oncology, vol. 24, no. 25, pp. 4202–4208, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Rutkowski, U. Bode, F. Deinlein et al., “Treatment of early childhood medulloblastoma by postoperative chemotherapy alone,” The New England Journal of Medicine, vol. 352, no. 10, pp. 978–986, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Pajouhesh and G. R. Lenz, “Medicinal chemical properties of successful central nervous system drugs,” NeuroRx, vol. 2, no. 4, pp. 541–553, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. K. von Hoff, B. Hinkes, N. U. Gerber et al., “Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91,” European Journal of Cancer, vol. 45, no. 7, pp. 1209–1217, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. D. Ris, R. Packer, J. Goldwein, D. Jones-Wallace, and J. M. Boyett, “Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a children's cancer group study,” Journal of Clinical Oncology, vol. 19, no. 15, pp. 3470–3476, 2001. View at Google Scholar · View at Scopus
  10. A. W. Walter, R. K. Mulhern, A. Gajjar et al., “Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital,” Journal of Clinical Oncology, vol. 17, no. 12, pp. 3720–3728, 1999. View at Google Scholar · View at Scopus
  11. R. Soffietti, R. Ruda, and R. Mutani, “Management of brain metastases,” Journal of Neurology, vol. 249, no. 10, pp. 1357–1369, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Rutkauskiene and L. Labanauskas, “Treatment of patients of high-risk group of medulloblastoma with the adjuvant lomustine, cisplatin, and vincristine chemotherapy,” Medicina, vol. 41, no. 12, pp. 1026–1034, 2005. View at Google Scholar · View at Scopus
  13. R. L. Smith, X. Shi, and E. J. Estin, “Chemotherapy dose-intensity and survival for childhood medulloblastoma,” Anticancer Research, vol. 32, no. 9, pp. 3885–3892, 2012. View at Google Scholar
  14. G. M. Lewandowicz, B. Harding, W. Harkness, R. Hayward, D. G. T. Thomas, and J. L. Darling, “Chemosensitivity in childhood brain tumours in vitro: evidence of differential sensitivity to lomustine (CCNU) and vincristine,” European Journal of Cancer, vol. 36, no. 15, pp. 1955–1964, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Ekins, J. Mestres, and B. Testa, “In silico pharmacology for drug discovery: applications to targets and beyond,” British Journal of Pharmacology, vol. 152, no. 1, pp. 21–37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. H. van de Waterbeemd, G. Camenisch, G. Folkers, J. R. Chretien, and O. A. Raevsky, “Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors,” Journal of Drug Targeting, vol. 6, no. 2, pp. 151–165, 1998. View at Google Scholar · View at Scopus
  17. C. A. Lipinski, “Drew University Medical Chemistry Special Topics Course,” July 1999.
  18. S. T. Bow, Pattern Recognition, Marcel Dekker, New York, NY, USA, 1984.
  19. C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings,” Advanced Drug Delivery Reviews, vol. 46, no. 1–3, pp. 3–26, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. D. E. Clark, “Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration,” Journal of Pharmaceutical Sciences, vol. 88, no. 8, pp. 815–821, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. B. S. Everitt and G. Dunn, Applied Multivariate Data Analysis, Edward Arnold, London, UK, 1991.
  22. E. O. Vik-Mo, C. Sandberg, H. Olstorn et al., “Brain tumor stem cells maintain overall phenotype and tumorigenicity after in vitro culturing in serum-free conditions,” Neuro-Oncology, vol. 12, no. 12, pp. 1220–1230, 2010. View at Publisher · View at Google Scholar · View at Scopus